Table 1.
Patient characteristics
| Baseline demographics | Arm A (G/NP+P) N=24 |
Arm B (G/NP) N=13 |
Total N=37 |
| Age group | |||
| 18–64 years | 10 (41.7%) | 8 (61.5%) | 18 (48.6%) |
| 65–74 years | 10 (41.7%) | 4 (30.8%) | 14 (37.8%) |
| ≥75 years | 4 (16.7%) | 1 (7.7%) | 5 (13.5%) |
| Median | 67 | 62 | 66 |
| Sex | |||
| Male | 8 (33.3%) | 6 (46.2%) | 14 (37.8%) |
| Female | 16 (66.7%) | 7 (53.8%) | 23 (62.2%) |
| BMI (kg/m2) | |||
| Mean (SD) | 25.27 (4.303) | 26.69 (4.757) | 25.77 (4.455) |
| Median | 25.5 | 28.3 | 25.7 |
| Min, max | (18.4 to 37.5) | (19.3 to 33.8) | (18.4 to 37.5) |
| ECOG | |||
| Grade 0 | 9 (37.5%) | 7 (53.8%) | 16 (43.2%) |
| Grade 1 | 15 (62.5%) | 6 (46.2%) | 21 (56.8%) |
| TNM stage | |||
| T3 N0 M0 | 6 (25.0%) | 0 | 6 (16.2%) |
| T3 N1 M0 | 0 | 2 (15.4%) | 2 (5.4%) |
| T4 N0 M0 | 14 (58.3%) | 7 (53.8%) | 21 (56.8%) |
| T4 N1 M0 | 3 (12.5%) | 4 (30.8%) | 7 (18.9%) |
| T4 NX M0 | 1 (4.2%) | 0 | 1 (2.7%) |
| Location of the tumour in the pancreas* | |||
| Head | 18 (75.0%) | 11 (84.6%) | 29 (78.4%) |
| Body | 7 (29.2%) | 2 (15.4%) | 9 (24·.3%) |
| Tail | 1 (4.2%) | 2 (15.4%) | 3 (8.1%) |
| Median tumour size (mm) | 37 | 38 | 37 |
| Non-resectability per NCCN criterion* | |||
| >180° SMA encasement | 11 (45.8%) | 3 (23.1%) | 14 (37.8%) |
| Any coeliac abutment | 9 (37.5%) | 6 (46.2%) | 15 (40.5%) |
| Inferior vena cava invasion or encasement | 1 (4.2%) | 1 (7.7%) | 2 (5.4%) |
| Unreconstructible SMV/portal occlusion | 9 (37.5%) | 5 (38.5%) | 14 (37.8%) |
| Aortic invasion and encasement | 1 (4.2%) | 0 | 1 (2.7%) |
OK as is
*Not mutually exclusive.
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; G, gemcitabine; n, number of subjects; NCCN, National Comprehensive Cancer Network; NP, nab paclitaxel; P, pamrevlumab; PV, portal vein; SMA, superior mesenteric artery; SMV, superior mesenteric vein.